Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

This trial is testing a combination of three treatments — cadonilimab (an immunotherapy drug), fruquintinib (a targeted drug that cuts off blood supply to tumors), and SBRT (focused radiation) — in people with advanced colorectal cancer that has not responded to standard chemotherapy and whose tumors are of the MSS type (which typically does not respond well to immunotherapy alone). **You may be eligible if...** - You are 18–75 years old with Stage IV colorectal cancer - Your tumor is MSS (microsatellite stable) - You have tried at least two prior standard chemotherapy regimens and they stopped working - You are in good overall health (ECOG 0-1) and have measurable tumors - Your liver, kidney, and blood counts are within acceptable ranges **You may NOT be eligible if...** - You have previously received immunotherapy (such as PD-1 or PD-L1 drugs) - You have a serious autoimmune disease, active infection, or lung disease - You have serious bleeding problems, recent stroke, or uncontrolled blood pressure - You are pregnant or breastfeeding - You have HIV or active hepatitis B/C Talk to your doctor to see if this trial is right for you.